seletalisib
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT02303509)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1- Mol. weight
- 482.85 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297648 ↗
Also known as
- seletalisib
- ucb5857
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02610543 | Phase 2 | Oct 1, 2015 | Hoosier Cancer Research Network, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT02207595 | Phase 1 | Aug 1, 2014 | Hoosier Cancer Research Network, Parexel |
| NCT02303509 | Phase 1 | Aug 1, 2013 | Hoosier Cancer Research Network, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 3 | 3 | 2 | 2013 |
| Parexel | For profit | 2 | 0 | 1 | 2013 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1